The transaction, which closed on March 20, 2026, involves the issuance of 10,485 shares of Series A convertible non-redeemable preferred stock, along with Series B and Series C warrants that allow for the purchase of up to 85,233,126 shares of the company's common stock. Each share of Series A Preferred Stock is bundled with warrants to purchase additional shares, effectively enhancing the investment's value for the purchasers.
The proceeds from this financing will be utilized to bolster Azitra's research and development efforts, support general corporate expenses, and meet working capital needs. The company aims to leverage its expertise in skin science and its microbial genetic engineering platform to develop high-value proteins and peptides targeted at the cosmetic market, which is projected to grow significantly in the coming years.
Azitra's Chief Executive Officer, Francisco Salva, expressed enthusiasm about the financing, stating that it positions the company to accelerate its innovative programs, particularly those focused on developing proprietary filaggrin protein and peptide technologies. These advancements are expected to address common dermatological issues such as fine lines, wrinkles, and skin conditions like eczema.
The financing also includes provisions for the registration of the shares and warrants, ensuring compliance with federal and state securities laws. This strategic move not only strengthens Azitra's financial position but also enhances its capacity to attract new strategic partners in the burgeoning biotech-oriented cosmetic ingredients market, which reached $2.3 billion in 2024 and is anticipated to expand to $3.7 billion by 2030.
Overall, this financing marks a significant milestone for Azitra, providing the necessary capital to advance its innovative research initiatives and solidify its position in the dermatological and cosmetic sectors.
